Citations

Clear

4847 citation(s) found for "Yu, Eric".

Esophageal Pathophysiologic Changes and Adenocarcinoma After Bariatric Surgery: A Systematic Review and Meta-Analysis
Jaruvongvanich, Veeravich , Matar, Reem , Vantanasiri, Kornpong , Wongjarupong, Nicha , Ungprasert, Patompong , Maselli, Daniel B. , Abu Dayyeh, Barham K, Matar, Reem , Ravi, Karthik , Murad, M. Hassan , Vargas, Eric J. , Prokop, Larry J. , Dayyeh, Barham K. Abu

Mayo Clinic

Clinical and Translational Gastroenterology | August 24, 2020 | Volume: 11 | Issue: 8 | Pages: e00225

10.14309/ctg.0000000000000225 | PMID 32955206 Get It

INTRODUCTION: To assess the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on acid reflux and esophageal motor function and to evaluate the observation of esophageal adenocarcinoma (EAC) after bariatric surgery. METHODS: We searched 5 databases for adults who underwent SG or RYGB and had esophageal pH test and/or esophageal manometry before and after surgery. A separate systemic search of observational studies and a retrospective review at 3 institutions of adults who developed EAC after these surgeries were conducted. Outcomes were changes in manometric and pH parameters and EAC cases after SG and RYGB. RESULTS: A total of 27 nonrandomized studies (SG: 612 patients; RYGB: 470 patients) were included. After SG, lower esophageal sphincter pressure and esophageal body amplitude were decreased and the risk of ineffective esophageal motility was increased. Total and recumbent acid exposure times were increased. After RYGB, an increased risk of ineffective esophageal motility was observed. Total, upright, and recumbent acid exposure times were decreased. The total reflux episodes remained unchanged but with increased nonacid reflux and decreased acid reflux events. Including our largest series, 31 EAC cases have been reported to date after SG and RYGB. DISCUSSION: This systematic review demonstrates increased acid reflux after SG and decreased acid reflux after RYGB. An observed increased nonacid reflux after RYGB might contribute to failure of gastroesophageal reflux disease improvement. This refluxate might be noxious to the esophagus, warranting further studies. RYGB might not entirely preserve esophageal function as previously believed.
The Institute for Healthcare Improvement–NeuroPoint Alliance collaboration to decrease length of stay and readmission after lumbar spine fusion: using national registries to design quality improvement protocols
Devin, Clinton J. , Rossi, Vincent , Chotai, Silky , Dyer, E. Hunter, Knightly, John J. , Potts, Eric A. , Foley, Kevin T. , Bisson, Erica F. , Glassman, Steven D. , Mummaneni, Praveen V. , Bydon, Mohamad , Asher, Anthony L. , Zuckerman, Scott L.

Mayo Clinic

Journal of Neurosurgery: Spine | August 21, 2020 | Volume: 33 | Issue: 6 | Pages: 812-821

10.3171/2020.5.spine20457 | PMID 32823267 Get It

OBJECTIVENational databases collect large amounts of clinical information, yet application of these data can be challenging. The authors present the NeuroPoint Alliance and Institute for Healthcare Improvement (NPA-IHI) program as a novel attempt to create a quality improvement (QI) tool informed through registry data to improve the quality of care delivered. Reducing the length of stay (LOS) and readmission after elective lumbar fusion was chosen as the pilot module.METHODSThe NPA-IHI program prospectively enrolled patients undergoing elective 1- to 3-level lumbar fusions across 8 institutions. A three-pronged approach was taken that included the following phases: 1) Research Phase, 2) Development Phase, and 3) Implementation Phase. Primary outcomes were LOS and readmission. From January to June 2017, a learning system was created utilizing monthly conference calls, weekly data submission, and continuous refinement of the proposed QI tool. Nonparametric tests were used to assess the impact of the QI intervention.RESULTSThe novel QI tool included the following three areas of intervention: 1) preoperative discharge assessment (location, date, and instructions), 2) inpatient changes (LOS rounding checklist, daily huddle, and pain assessments), and 3) postdischarge calls (pain, primary care follow-up, and satisfaction). A total of 209 patients were enrolled, and the most common procedure was a posterior laminectomy/fusion (60.2%). Seven patients (3.3%) were readmitted during the study period. Preoperative discharge planning was completed for 129 patients (61.7%). A shorter median LOS was seen in those with a known preoperative discharge date (67 vs 80 hours, p = 0.018) and clear discharge instructions (71 vs 81 hours, p = 0.030). Patients with a known preoperative discharge plan also reported significantly increased satisfaction (8.0 vs 7.0, p = 0.028), and patients with increased discharge readiness (scale 0–10) also reported higher satisfaction (r = 0.474, p < 0.001). Those receiving postdischarge calls (76%) had a significantly shorter LOS than those without postdischarge calls (75 vs 99 hours, p = 0.020), although no significant relationship was seen between postdischarge calls and readmission (p = 0.342).CONCLUSIONSThe NPA-IHI program showed that preoperative discharge planning and postdischarge calls have the potential to reduce LOS and improve satisfaction after elective lumbar fusion. It is our hope that neurosurgical providers can recognize how registries can be used to both develop and implement a QI tool and appreciate the importance of QI implementation as a separate process from data collection/analysis.
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
Wagner, Dorothea , André, Thierry , Dixon, Jesse G. , Haller, Daniel G. , Allegra, Carmen J. , Gramont, Aimery de , VanCutsem, Eric, George, Thomas J. , Twelves, Christopher , Taı̈eb, Julien , Blanke, Charles D. , Francini, Edoardo , Yothers, Greg , Seitz, Jean François, Marsoni, Silvia , Goldberg, Richard M. , Shi, Qian , George, Thomas J , André, Thierry , Shi, Qian , Yothers, Greg , Taieb, Julien , Marsoni, Silvia , Dixon, Jesse G , Grothey, Axel , Wolmark, Norman , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Kerr, Rachel

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 19, 2020 | Volume: 113 | Issue: 4 | Pages: 400-407

10.1093/jnci/djaa124 | PMID 32835356 Get It

Abstract Background Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal cancer are missing. Methods The objective of our study was to compare incidence and severity of major toxicities of fluoropyrimidine- (5FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult patients enrolled in 27 relevant randomized trials included in the ACCENT (Adjuvant Colon Cancer End Points) database, a large, multi-group, international data repository containing individual patient data, were included. Comparisons were conducted using logistic regression models (stratified by study and treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, capecitabine, CAPOX, and FOLFIRI). The following major toxicities were compared (grade III or IV and grade I-IV, according to National Cancer Institute Common Terminology Criteria [NCI-CTC] criteria, regardless of attribution): nausea, vomiting, nausea or vomiting, stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in patients treated with oxaliplatin). Results Data from 34 640 patients were analyzed. Statistically significant and clinically relevant differences in the occurrence of grade III or IV nonhematological {especially nausea (5FU: odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.90 to 2.87, P &lt; .001; FOLFOX: OR = 2.34, 95% CI = 1.76 to 3.11, P &lt; .001), vomiting (5FU: OR = 2.38, 95% CI = 1.86 to 3.04, P &lt; .001; FOLFOX: OR = 2.00, 95% CI = 1.50 to 2.66, P &lt; .001; CAPOX: OR = 2.32, 95% CI = 1.55 to 3.46, P &lt; .001), and diarrhea (5FU: OR = 1.35, 95% CI = 1.21 to 1.51, P &lt; .001; FOLFOX: OR = 1.60, 95% CI = 1.35 to 1.90, P &lt; .001; FOLFIRI: OR = 1.57, 95% CI = 1.25 to 1.97, P &lt; .001)} as well as hematological toxicities (neutropenia [5FU: OR = 1.55, 95% CI = 1.37 to 1.76, P &lt; .001; FOLFOX: OR = 1.96, 95% CI = 1.71 to 2.25, P &lt; .001; FOLFIRI: OR = 2.01, 95% CI = 1.66 to 2.43, P &lt; .001; capecitabine: OR = 4.07, 95% CI = 1.84 to 8.99, P &lt; .001] and leukopenia [5FU: OR = 1.74, 95% CI = 1.40 to 2.17, P &lt; .001; FOLFIRI: OR = 1.75, 95% CI = 1.28 to 2.40, P &lt; .001]) were observed, with women being consistently at increased risk. Conclusions Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation.
Polymyalgia Rheumatica and Giant Cell Arteritis
Buttgereit, Frank , Matteson, Eric L. , Dejaco, Christian , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

JAMA | August 19, 2020 | Volume: 324 | Issue: 10 | Pages: 993

10.1001/jama.2020.10155 | PMID 32897333 Get It

KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype
Zhang, Boyi , Long, Qilai , Wu, Shanshan , Song, Shuling, Xu, Qixia, Liu, Han , Qian, Min , Ren, Xiaohui , Jiang, Jing , Fu, Qiang , Guo, Jianming , Chang, Xing, Campisi, Judith , Kirkland, James L. , Qian, Min, Fu, Qiang, Zhang, Xiaoling , Lam, Eric W.‐F. , Sun, Yu

Mayo Clinic

No container title available | August 17, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-52927/v1 Get It

Abstract Cellular senescence restrains the expansion of neoplastic cells through several layers of regulation, including epigenetic decoration of chromatin structure and functional modulation of bioactive components. Here we report that expression of the histone H3-specific demethylase KDM4 is upregulated in human stromal cells upon cellular senescence. In clinical oncology, upregulated KDM4 and diminished H3K9/H3K36 methylation are correlated with adverse survival of cancer patients post-chemotherapy. Global chromatin accessibility mapping via ATAC-seq and expression profiling through RNA-seq reveal extensive reorganization of chromosomes and spatiotemporal reprogramming of the transcriptomic landscape, events responsible for development of the senescence-associated secretory phenotype (SASP). Selectively targeting KDM4 dampens the SASP of senescent stromal cells and enhances the apoptotic index of cancer cells in the treatment-damaged tumor microenvironment (TME), together prolonging overall survival of experimental animals. Our study supports the dynamic change of H3K9/H3K36 methylation marks during cellular senescence, identifies an unusually permissive chromatin state, unmasks KDM4 as a key modulator of the SASP, and presents a novel therapeutic avenue to manipulate cellular senescence and curtail age-related pathologies.
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Connolly, Roisín M. , Laille, Eric , Vaishampayan, Ulka N. , Dowlati, Afshin , Alese, Olatunji B. , Harvey, R. Donald , Siu, Lillian L. , Anders, Nicole M. , Downs, Melinda, O’Connor, Ashley , Scardina, Angela, Saunders, Jacqueline , Rosner, Gary L. , Carducci, Michael A., Alese, Olatunji B , Harvey, R Donald , Haluska, Paul , Siu, Lillian L , Saunders, Jacqueline , Rudek, Michelle A. , Vaishampayan, Ulka , Chung, Vincent , Kelly, Karen , Kummar, Shivaani , Piekarz, Richard , Ivy, S. Percy

Mayo Clinic

Clinical Cancer Research | August 14, 2020 | Volume: 26 | Issue: 20 | Pages: 5329-5337

10.1158/1078-0432.ccr-20-1412 | PMID 32816943 Get It

Abstract Purpose: Romidepsin dosing recommendations for patients with malignancy and varying degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell lymphoma. We conducted a multicenter phase I clinical trial (ETCTN-9008) via the NCI Organ Dysfunction Working Group to investigate safety, first cycle MTD, and pharmacokinetic profile of romidepsin in this setting. Patients and Methods: Patients with select advanced solid tumors or hematologic malignancies were stratified according to hepatic function. Romidepsin was administered intravenously on days 1, 8, and 15 of a 28-day cycle and escalation followed a 3 + 3 design in moderate and severe impairment cohorts. Blood samples for detailed pharmacokinetic analyses were collected after the first dose. Results: Thirty-one patients received one dose of romidepsin and were evaluable for pharmacokinetic analyses in normal (n = 12), mild (n = 8), moderate (n = 5), and severe (n = 6) cohorts. Adverse events across cohorts were similar, and dose-limiting toxicity occurred in two patients (mild and severe impairment cohorts). The MTD was not determined because the geometric mean AUC values of romidepsin in moderate (7 mg/m2) and severe (5 mg/m2) impairment cohort were 114% and 116% of the normal cohort (14 mg/m2). Conclusions: Data from the ETCTN-9008 trial led to changes in the romidepsin labeling to reflect starting dose adjustment for patients with cancer and moderate and severe hepatic impairment, with no adjustment for mild hepatic impairment.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Abida, Wassim , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Piulats, Josep M. , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Loehr, Andrea , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, investigators, on behalf of the TRITON2, Bryce, Alan H , Watkins, Simon P , Daugaard, Gedske , McDermott, Ray , Patnaik, Akash , Vogelzang, Nicholas J. , Sternberg, Cora N , investigators, on behalf of the TRITON2

Mayo Clinic

Journal of Clinical Oncology | August 14, 2020 | Volume: 38 | Issue: 32 | Pages: 3763-3772

10.1200/jco.20.01035 | PMID 32795228 Get It

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate-specific antigen (PSA) response (≥ 50% decrease from baseline) rate. RESULTS Efficacy and safety populations included 115 patients with a BRCA alteration with or without measurable disease. Confirmed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.7%; 27 of 62 patients) and 50.8% (95% CI, 38.1% to 63.4%; 33 of 65 patients), respectively. The confirmed PSA response rate was 54.8% (95% CI, 45.2% to 64.1%; 63 of 115 patients). ORRs were similar for patients with a germline or somatic BRCA alteration and for patients with a BRCA1 or BRCA2 alteration, while a higher PSA response rate was observed in patients with a BRCA2 alteration. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (25.2%; 29 of 115 patients). CONCLUSION Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
What are the predictors of emergency department utilization and readmission following extremity bone sarcoma resection?
Wellings, Elizabeth P. , Wilke, Benjamin K. , Asante, Dennis, Sangaralingham, Lindsey R. , Rose, Peter S. , Moran, Steven L. , Houdek, Matthew T. , Wagner, Eric R. , Wilke, B K , Houdek, Matthew T

Mayo Clinic

Journal of Surgical Oncology | August 14, 2020 | Volume: 122 | Issue: 7 | Pages: 1356-1363

10.1002/jso.26173 | PMID 32794224 Get It

AbstractIntroductionTreatment for bone sarcomas are large undertakings. Emergency department (ED) visits and unplanned hospital readmissions are a potential target for cost containment. The purpose of this study was to evaluate the risk factors for ED visits and unplanned readmissions following extremity bone sarcoma surgery.MethodsData from Optum Labs Data Warehouse, a national administrative claims database, was analyzed to identify patients with extremity bone sarcomas from 2006 to 2017. Multivariable logistic regression was used to identify factors associated with ED visits and readmissions.ResultsOf 1390 (743 males, 647 female) adult patients, 137 (12%) visited the ED and 245 (18%) were readmitted within 30 days of discharge. The most common indication for ED visits (n = 63, 45.9%) and readmission (n = 119, 48.5%) were complications of surgery. Length of stay >10 days was associated with ED utilization (OR, 1.83; P = .01) and readmission (OR, 4.47; P < .001).ConclusionOne in ten patients will use the ED, and one in five patients will be readmitted to the hospital within 30 days of discharge following extremity bone sarcoma surgery. Length of stay was associated with ED visits and readmission. These patients could be targeted with alternative management strategies in the outpatient setting with early clinical follow‐up to minimize readmission.
Incorporating multiple sets of eQTL weights into gene‐by‐environment interaction analysis identifies novel susceptibility loci for pancreatic cancer
Yang, Tianzhong , Tang, Hongwei, Olson, Sarah, Peterson, Gloria, Bracci, Paige M. , Gallinger, Steven , Hung, Rayjean J., Scélo, Ghislaine , Kurtz, Robert C. , Sund, Malin , Wareham, Nick, Li, Donghui , Wareham, Nicholas J. , Wei, Peng , Sund, Malin , Risch, Harvey A. , Hung, Rayjean J., Neale, Rachel Ε. , Duell, Eric J. , Khaw, Kay‐Tee , Severi, Gianluca , Amos, Christopher I. , Wei, Peng

Mayo Clinic

Genetic Epidemiology | August 11, 2020 | Volume: 44 | Issue: 8 | Pages: 880-892

10.1002/gepi.22348 | PMID 32779232 Get It

AbstractIt is of great scientific interest to identify interactions between genetic variants and environmental exposures that may modify the risk of complex diseases. However, larger sample sizes are usually required to detect gene‐by‐environment interaction (G × E) than required to detect genetic main association effects. To boost the statistical power and improve the understanding of the underlying molecular mechanisms, we incorporate functional genomics information, specifically, expression quantitative trait loci (eQTLs), into a data‐adaptive G × E test, called aGEw. This test adaptively chooses the best eQTL weights from multiple tissues and provides an extra layer of weighting at the genetic variant level. Extensive simulations show that the aGEw test can control the Type 1 error rate, and the power is resilient to the inclusion of neutral variants and noninformative external weights. We applied the proposed aGEw test to the Pancreatic Cancer Case–Control Consortium (discovery cohort of 3,585 cases and 3,482 controls) and the PanScan II genome‐wide association study data (replication cohort of 2,021 cases and 2,105 controls) with smoking as the exposure of interest. Two novel putative smoking‐related pancreatic cancer susceptibility genes, TRIP10 and KDM3A, were identified. The aGEw test is implemented in an R package aGE.
Peptide Vaccine with Glucopyranosyl Lipid A–Stable Oil-in-Water Emulsion for Patients with Resected Melanoma
Grewal, Eric P. , Erskine, Courtney L. , Nevala, Wendy K. , Allred, Jacob B., Kottschade, Lisa A. , Dronca, Roxana , Yakovich, Adam J., Block, Matthew S. , McWilliams, Robert R. , Dronca, Roxana S., Block, Matthew S , Grewal, Eric P , Strand, Carrie , Markovic, Svetomir N.

Mayo Clinic

Immunotherapy | August 5, 2020 | Volume: 12 | Issue: 13 | Pages: 983-995

10.2217/imt-2020-0085 | PMID 32752904 Get It